Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2877810 | 0.83 | P2RX3 (0.63) | P2RX3 | |
| SCHEMBL2849649 | 0.76 | P2RX3 (0.72) | P2RX3 | |
| SCHEMBL12973601 | 0.73 | P2RX3 (0.54) | P2RX3 | |
| SCHEMBL2849790 | 0.73 | P2RX3 (0.51) | P2RX3 | |
| SCHEMBL12973540 | 0.73 | P2RX3 (0.63) | P2RX3 | |
| SCHEMBL2876998 | 0.72 | P2RX3 (0.63) | P2RX3 | |
| SCHEMBL12973554 | 0.72 | P2RX3 (0.56) | P2RX3 | |
| SCHEMBL12973581 | 0.71 | P2RX3 (0.61) | P2RX3 | |
| SCHEMBL996761 | 0.71 | P2RX3 (0.62) | P2RX3 | |
| SCHEMBL997013 | 0.71 | P2RX3 (0.60) | P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885369-B1 | FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2015-09-23 | — | — | EP | claimed |
| US-20100317676-A1 | Fused heterocyclic compounds, and compositions and uses thereof | RENOVIS, INC. | 2010-12-16 | — | — | US | claimed |
| US-7745451-B2 | 2,3-Difluoro-benzyl)-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine, useful for the prevention and treatment of pain, inflammation, cognitive disorders, anxiety and depression in humans | RENOVIS, INC. (US) | 2010-06-29 | — | — | US | claimed |
| US-20060258689-A1 | 2,3-Difluoro-benzyl)-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine, useful for the prevention and treatment of pain, inflammation, cognitive disorders, anxiety and depression in humans | EVOTEC SE (DE) | 2006-11-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258689-A1 | 2,3-Difluoro-benzyl)-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine, useful for the prevention and treatment of pain, inflammation, cognitive disorders, anxiety and depression in humans | BDNF, OPRL1, GRIN2D | P2RX3 97/4885OGA 3929/4885 |
| US-20100317676-A1 | Fused heterocyclic compounds, and compositions and uses thereof | OPRL1, OPRK1, IL1B | P2RX3 281/4885OGA 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.